In this episode of the Biotech and Life Sciences CEO podcast, we meet with Berkshire Biomedical CEO John Timberlake to discuss how they are making innovations in personalized medication delivery. Through their COPA product, which stands for Computerized Oral Prescription Administration, they are coming up with new ways to ensure that liquid medications are delivered at the right time, in the right amount, and only to the authenticated, intended user. For more episodes of inspirational Biotech and Life Sciences CEOs, visit our podcast site: https://www.biotechinsights.net/
Tim Dougherty
tim@biotechinsights.net
About John Timberlake John Timberlake has served as Berkshire Biomedical’s Chief Executive Officer, President, and a member of our Board of Directors since April 2021. Mr. Timberlake has more than 30 years of life sciences experience in bringing pharmaceuticals, medical devices, and drug-device combination products to market. Most recently, Mr. Timberlake was chief executive officer, president, and a member of the board of directors for Valeritas Holdings, Inc. During his fourteen‐year tenure at Valeritas, he advanced from General Manager to Chief Commercial Officer, and ultimately to Chief Executive Officer and Board Member in February 2016. Mr. Timberlake commercialized their lead product, V‐Go®; took the company public; and executed the sale of the company to Zealand Pharma in April 2020. For the fifteen years prior to Valeritas, he held varying leadership roles across corporate finance, and the commercial organization at Sanofi and its predecessor companies. As Director of New Product Commercialization for Metabolism and subsequently Vice President of Diabetes Portfolio Brand Management for Sanofi, he was instrumental in creating the multi‐billion‐dollar diabetes franchise of insulins and oral antidiabetic prescription products, including Lantus®, the company's block-buster basal insulin. Prior to that, he was an auditor with Deloitte and left the firm after five years as an Audit Manager. Mr. Timberlake was both a certified management accountant and a certified public accountant. He earned his Bachelor of Science in Accounting at Northwest Missouri State University, a Master of Science in Management at the Krannert School of Management, Purdue University, and a Master of Business Administration at the ESC Rouen in Rouen, France (now the NEOMA Business School).
Disclaimers The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.
